Citigroup Inc Immutep LTD Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$1.6 - $2.53 $6,299 - $9,960	-3,937 Reduced 98.55%	58 $0
Q3 2022 Nov 10, 2022	BUY	$1.56 - $2.29 $6,140 - $9,013	3,936 Added 6671.19%	3,995 $6,000
Q2 2022 Aug 10, 2022	SELL	$1.96 - $3.09 $3,945 - $6,220	-2,013 Reduced 97.15%	59 $0
Q1 2022 May 12, 2022	BUY	$2.3 - $3.61 $4,657 - $7,310	2,025 Added 4308.51%	2,072 $6,000
Q4 2021 Feb 10, 2022	BUY	$3.09 - $4.81 $145 - $226	47 New	47 $0

2.41M

526K

222K

Ticker IMMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,000
Market Cap $172M
Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.